Cellaion Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Liquidation
Cellaion General Information
Description
Operator of a biotechnology firm intended to develop advanced therapies aiming to repair tissues and regenerate organs. The company generates products with specific targets in the field of inflammation and degenerative diseases to restore the human body's regenerative process and to support the survival of a failing native liver, enabling pharmaceutical companies to create treatments based on allogeneic adult liver stem cells.
Contact Information
Website
www.cellaion.comCorporate Office
- Watson and Crick Hill
- Rue Granbonpré, 11
- 1435 Mont-Saint-Guibert
- Belgium
Corporate Office
- Watson and Crick Hill
- Rue Granbonpré, 11
- 1435 Mont-Saint-Guibert
- Belgium
Cellaion Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Bankruptcy: Liquidation | 27-May-2024 | Completed | Bankruptcy: Liquidation | |||
| 11. Later Stage VC | 18-Jan-2023 | Completed | Clinical Trials - Phase 2 | |||
| 10. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 9. Later Stage VC | 15-Feb-2022 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC | 30-Jun-2021 | Cancelled | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series D) | 09-Jan-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC (Series C) | 24-May-2017 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series C) | 25-Nov-2014 | Completed | Startup | |||
| 4. Grant | 11-Mar-2014 | $38.5M | Completed | Startup | ||
| 3. Early Stage VC (Series B) | 13-Jun-2013 | $30.7M | $38.5M | Completed | Startup |
Cellaion Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Class D | ||||||||
| Class D | ||||||||
| Class D | ||||||||
| Class B | ||||||||
| Class D | ||||||||
| Class B | ||||||||
| Class B | ||||||||
| Preference | 81,086 | $125.31 | $125.31 | 1x | $125.31 | 8.48% | ||
| Class A | 31,455 | $104.43 | $104.43 | 1x | $104.43 | 3.29% |
Cellaion Comparisons
Industry
Financing
Details
Cellaion Competitors (56)
One of Cellaion’s 56 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Alentis Therapeutics | Venture Capital-Backed | Allschwil, Switzerland | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA |
Cellaion Patents
Cellaion Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4560009-A1 | Method for the preparation of isolated liver-derived cells | Inactive | 27-Nov-2023 | ||
| EP-3881853-A1 | Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation | Inactive | 20-Mar-2020 | ||
| AU-2020364951-A1 | Use of liver progenitor or stem cells, lysates thereof, and/or conditioned medium in disorders characterized by vascular hyperpermeability | Inactive | 09-Oct-2019 | ||
| CA-3156655-A1 | Use of liver progenitor or stem cells, lysates thereof, and/or conditioned medium in disorders characterized by vascular hyperpermeability | Pending | 09-Oct-2019 | ||
| EP-4041261-A1 | Use of liver progenitor or stem cells, lysates thereof, and/or conditioned medium in disorders characterized by vascular hyperpermeability | Inactive | 09-Oct-2019 | A61K35/407 |
Cellaion Signals
Cellaion Investments & Acquisitions (3)
Cellaion’s most recent deal was a Joint Venture with Aceso & Promethera (Joint Venture) for . The deal was made on 14-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aceso & Promethera (Joint Venture) | 14-Jul-2020 | Joint Venture | Pharmaceuticals | ||
| Baliopharm | 10-Apr-2018 | Merger/Acquisition | Drug Discovery | ||
| Cytonet | 18-Apr-2016 | Merger/Acquisition | Biotechnology |
Cellaion Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Baliopharm | Basel, Switzerland | 2006 |
Cellaion FAQs
-
When was Cellaion founded?
Cellaion was founded in 2009.
-
Where is Cellaion headquartered?
Cellaion is headquartered in Mont-Saint-Guibert, Belgium.
-
What is the size of Cellaion?
Cellaion has 15 total employees.
-
What industry is Cellaion in?
Cellaion’s primary industry is Drug Discovery.
-
Is Cellaion a private or public company?
Cellaion is a Private company.
-
What is Cellaion’s current revenue?
The current revenue for Cellaion is .
-
How much funding has Cellaion raised over time?
Cellaion has raised $169M.
-
Who are Cellaion’s competitors?
Centrose, Marengo Therapeutics, Alentis Therapeutics, Inovio Pharmaceuticals, and Sangamo Therapeutics are some of the 56 competitors of Cellaion.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process